RedHill Biopharma (NASDAQ:RDHL) Stock Passes Below Two Hundred Day Moving Average of $1.51
RedHill Biopharma (NASDAQ:RDHL) Stock Passes Below Two Hundred Day Moving Average of $1.51
RedHill Biopharma Ltd. (NASDAQ:RDHL – Get Rating)'s stock price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.51 and traded as low as $0.94. RedHill Biopharma shares last traded at $1.02, with a volume of 1,519,624 shares traded.
納斯達克週三交易中，紅山生物的股價跌破200日移動均線，200日移動均線切入位為1.51美元，最低交易價格為0.94美元。紅山生物的股票最新報1.02美元，成交量為1,519,624股。
RedHill Biopharma Price Performance
紅山生物醫藥的價格表現
The company's 50 day moving average is $0.91 and its 200 day moving average is $1.51. The company has a current ratio of 0.98, a quick ratio of 0.79 and a debt-to-equity ratio of 9.42. The stock has a market capitalization of $53.74 million, a price-to-earnings ratio of -0.54 and a beta of 1.86.
該公司的50日移動均線切入位在0.91美元，200日移動均線切入位在1.51美元。該公司的流動比率為0.98，速動比率為0.79，債務權益比率為9.42。該股市值為5,374萬美元，市盈率為-0.54倍，貝塔係數為1.86。
RedHill Biopharma (NASDAQ:RDHL – Get Rating) last announced its quarterly earnings results on Thursday, June 23rd. The biotechnology company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.10. RedHill Biopharma had a negative net margin of 110.31% and a negative return on equity of 822.29%. The firm had revenue of $18.24 million for the quarter. During the same quarter in the prior year, the business earned ($0.53) earnings per share. Research analysts anticipate that RedHill Biopharma Ltd. will post -0.95 EPS for the current fiscal year.
紅山生物科技(納斯達克代碼：RDHL-GET Rating)上一次公佈季度收益是在6月23日星期四。這家生物技術公司公佈了本季度每股收益(0.30美元)，比普遍預期的(0.40美元)高出0.10美元。紅山生物醫藥的淨利潤率為負110.31%，淨資產回報率為負822.29%。該公司本季度的收入為1824萬美元。在去年同一季度，該業務實現了每股收益(0.53美元)。研究分析師預計，紅山生物製藥有限公司本財年的每股收益將達到0.95美元。
Institutional Inflows and Outflows
機構資金流入和流出
About RedHill Biopharma
關於雷德希爾生物醫藥公司
(Get Rating)
(獲取評級)
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.
紅山生物製藥有限公司是一家專業的生物製藥公司，主要專注於胃腸道和傳染病。該公司推廣胃腸藥物，包括用於治療患有慢性非癌症疼痛的成人阿片類藥物引起的便祕的Movantik；用於治療成人幽門螺桿菌感染的Talicia；以及用於治療成人旅行者腹瀉的Aemcolo。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on RedHill Biopharma (RDHL)
- PENN Entertainment Stock is Reset and Ready to Rebound
- 3 Payroll Software Makers Set For Growth In 2023
- NYSE Stocks Give Investors a Variety of Quality Options
- Zoom Video Communications Valuation Is Realigned With Reality
- The J.M. Smucker Company Proves Why Staples Are Outperforming
- 免費獲取StockNews.com關於RedHill Biophma(RDHL)的研究報告
- 賓夕法尼亞娛樂公司股票重置，準備反彈
- 3家薪資軟件製造商將在2023年實現增長
- 紐約證交所股票為投資者提供多種優質選擇
- ZOOM視頻通信估值與現實重新接軌
- J.M.斯莫克公司證明瞭史泰博表現優異的原因
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
接受《紅山生物報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對RedHill Biophma和相關公司的最新新聞和分析師評級的每日簡要摘要。